Mandate

Vinge advises Ovako Group in connection with the acquisition of BE Group’s operations in China

June 07, 2013

Vinge has advised Ovako Group in connection with the acquisition of the entire issued share capital in BE (Shanghai) Steel Trading Co., Ltd from BE Group AB (publ). The transaction is subject to approval by the relevant public authorities in China.

Ovako is a leading European producer of engineering steel for customers in the bearing, transport and manufacturing industries. The company has 11 production sites and a number of sales companies in Europe and the USA. Sales in 2012 amounted to EUR 937 million and the company had 3,040 employees. The total production capacity is 1.3 million tonnes of steel per year. The potential acquisition is intended to accelerate Ovako’s plans to establish a service centre in China in order to support Ovako’s customers in Asia by providing specific, niche products.

Vinge’s team advising Ovako Group consisted of partner Henrik Wenckert and associate Nina Farrahi. Partner Qun Gu advised on issues relating to China and Chinese law.

Related

Vinge advises Irisity in connection with issue of units

Vinge advises Irisity AB (publ) in connection with its rights issue of units consisting of shares and warrants. The issue is guaranteed to 80 per cent through subscription commitments and external guarantors.
October 03, 2024

Vinge has advised the municipality of Varberg in legal proceedings regarding a detailed development plan for a new residential area

The detailed development plan for approximately 50 new homes in Trönningenäs, north of the city of Varberg, was adopted by the municipality on 23 February 2023. It was subsequently appealed in several stages. By decision of the Land and Environment Court of Appeal, the plan become legally binding on 2 October 2024.
October 03, 2024

Vinge has advised Egetis Therapeutics in connection with directed share issuances

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with directed share issuances whereby Egetis Therapeutics receives gross proceeds of SEK 300 million.
October 03, 2024